Gleiss Lutz has advised Sunshine Lake Pharma on the German-law aspects of its listing on the Hong Kong Stock Exchange and the privatisation of its subsidiary YiChang HEC.
In connection with the listing of Sunshine Lake Pharma, Gleiss Lutz has issued a legal opinion on Sunshine Lake Pharma's German material subsidiary HEC Pharm GmbH.
The privatisation was effected by way of merger by absorption of YiChang HEC by Sunshine Lake Pharma, under which new H shares of Sunshine Lake Pharma were offered as consideration to acquire the H shares held by the relevant shareholders of YiChang HEC. The privatisation and listing were inter-conditional, upon completion of which YiChang HEC was delisted and Sunshine Lake Pharma was listed on the Hong Kong Stock Exchange with the YiChang HEC shareholders in the privatisation becoming Sunshine Lake Pharma’s shareholders by way of share exchange.
Sunshine Lake Pharma is a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products with a focus on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars.
The following Gleiss Lutz team led by Dr. Michael Burian (partner, Frankfurt) and Dr. Yixiao Li (both M&A, Stuttgart) has advised Sunshine Lake Pharma:
Dr. Anselm Christiansen (partner, Stuttgart), Sonja Hilgert (Berlin), Alexandra Brücher (all M&A, Stuttgart), Dr. Stephan Aubel (partner, Capital Markets, Frankfurt), Dr. Enno Burk (partner), Christoph Schoppe, Dr. Xiao Chen (all Healthcare & Life Sciences, all Berlin), Dr. Jacob von Andreae (partner), Aylin Hoffs (counsel, both Foreign Trade Law, both Düsseldorf), Dr. Ocka Stumm (partner), Dr. Johannes Heck (both Tax, both Frankfurt), Josefine Chakrabarti (counsel, Employment, Berlin), Maximilian Leisenheimer (Real Estate, Frankfurt), Dr. Simon Wagner (counsel, Commercial, Stuttgart), Simon Clemens Wegman (Data Protection, Berlin).
Forward
